TG THERAPEUTICS, INC.

(TGTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insider Sell: Tg Therapeutics

01/10/2022 | 06:22am EDT


© MT Newswires 2022
All news about TG THERAPEUTICS, INC.
05/20Top Midday Decliners
MT
05/20TG Therapeutics' Shares Plummet After BofA Securities Initiates Coverage at Underperfor..
MT
05/20TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
AQ
05/20BofA Securities Starts TG Therapeutics at Underperform With $5 Price Target
MT
05/11SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Th..
PR
05/11TG THERAPEUTICS : Q1 Earnings Snapshot
AQ
05/10TG THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
05/10TG Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 20..
CI
04/27TG Therapeutics to Participate in the B. Riley Securities' 2022 Virtual Neuro & Ophthal..
AQ
04/26TG Therapeutics to Participate in the B. Riley Securities' 2022 Virtual Neuro & Ophthal..
AQ
More news
Analyst Recommendations on TG THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 21,6 M - -
Net income 2022 -264 M - -
Net cash 2022 11,7 M - -
P/E ratio 2022 -2,87x
Yield 2022 -
Capitalization 717 M 717 M -
EV / Sales 2022 32,6x
EV / Sales 2023 5,94x
Nbr of Employees 286
Free-Float 91,9%
Chart TG THERAPEUTICS, INC.
Duration : Period :
TG Therapeutics, Inc. Technical Analysis Chart | TGTX | US88322Q1085 | MarketScreener
Technical analysis trends TG THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 5,39 $
Average target price 19,63 $
Spread / Average Target 264%
EPS Revisions
Managers and Directors
Michael Sean Weiss Chairman, President & Chief Executive Officer
Sean A. Power Chief Financial Officer, Secretary & Treasurer
Owen A. O'Connor Chief Scientific Officer
Laurence N. Charney Lead Independent Director
Yann Echelard Independent Director
Sector and Competitors
1st jan.Capi. (M$)
TG THERAPEUTICS, INC.-71.63%717
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567